Loading insider details...
Latest Form 4 (Jun 3, 2026): Sale of 9,812 EXEL shares, $492.0K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | EXELIXIS, INC. (EXEL) | Sale | 9,812 | $492.0K |
| May 29, 2026 | EXELIXIS, INC. (EXEL) | Grant/Award | 8,367 | n/a |
| Feb 19, 2026 | EXELIXIS, INC. (EXEL) | Sale | 3,856 | $168.9K |
| Jun 4, 2025 | EXELIXIS, INC. (EXEL) | Sale | 18,834 | $805.0K |
| May 30, 2025 | EXELIXIS, INC. (EXEL) | Grant/Award | 9,812 | n/a |
| Feb 20, 2025 | EXELIXIS, INC. (EXEL) | Exercise/Conversion | 7,712 | $179.2K |
| Jun 7, 2024 | Syros Pharmaceuticals, Inc. (SYRS) | Grant/Award | 4,000 | n/a |
| Jun 5, 2024 | EXELIXIS, INC. (EXEL) | Grant/Award | 18,838 | n/a |
| Jan 10, 2024 | EXELIXIS, INC. (EXEL) | Grant/Award | 15,424 | n/a |
| Jun 2, 2023 | Syros Pharmaceuticals, Inc. (SYRS) | Grant/Award | 4,000 | n/a |